VISICORT PIs present at Societas Ophthalmologica Europæa

On June 16, 2019, Prof. Jesper Hjortdal, of the Aarhus University Hospital gave a presentation at the SOE (Societas Ophthalmologica Europæa, or European Society of Ophthalmology) on “Adverse immune signatures after corneal transplantation” based on the preliminary findings in the VISICORT study. This year the SOE held its bi-annual meeting in Nice, France. The symposium on “The Bad and Ugly Side of Corneal Grafting: How to Avoid and Manage Complications” was well attended.

VISICORT PI Prof. Conor Murphy, RCSI, the Royal College of Surgeons in Ireland also presented at the symposium. Conor’s presentation was titled: “Primary failure after corneal transplantation, definition and incidence”.

The SOE’s Society’s mission is to become the central point of European Ophthalmology primarily through education as well as fostering closer collaboration with Subspecialty Societies and Supranational Organisations within Europe and beyond.

International Clinical Trials Day 2019, Galway

The HRB Clinical Research Facility Galway in Ireland hosted a public event to celebrate International Clinical Trials Day on May 20th 2019. Exhibition stands were on display and informational meetings were held throughout the day to inform the public of all areas of clinical research being undertaken at the facility.

A particular stand was dedicated to the CRF Galway’s stem cell work to inform the public of the cell therapy projects being undertaken with partners within the National University of Ireland Galway and with European partners.  VISICORT was showcased here, as were the related projects NEPHSTROM and ADIPOA-2.

Great interest was expressed in this evolving therapeutic area with approximately 100 members of the public stopping by to hear about what cell therapy involves and to learn about the projects from the clinical researchers on the day.

Dr Veronica McInerney, CRF Galway
Dr Veronica McInerney, NUI Galway

Interview: Lisa Imrie, U of Edinburgh uses the VISICORT Biobank

Lisa Imrie, PhD candidate, University of Edinburgh uses VISICORT Foundation Biobank

Lisa Imrie is a Proteomics Specialist at the University of Edinburgh and a graduate of Edinburgh Napier University with a degree in microbiology and biotechnology. She has recently started her PhD studies taking a unique perspective in the analysis of biosamples from the VISICORT Foundation Biobank.

Danielle Nicholson, Pintail Limited caught up with Lisa Imrie after the latest plenary meeting in Galway to pose a few questions about her PhD research. In this interview (1 of 2), Lisa discusses her PhD project, how new techniques in the lab and with the data set analyses will carry the results of VISICORT forward and contribute to the field of proteomics.

What is the main focus of your PhD project?

To characterise different eye tissues and identify clinically relevant biomarkers in both keratoconus and Fuch’s Endothelial Corneal Dystrophy (FECD) using a multi-omics approach.

Why have you focussed on that in particular? What is it that interests you about it?

Until recently my career has been very technically orientated as I currently provide a proteomics service for a mass spectrometry core facility within the University of Edinburgh.  This has allowed me a brief snapshot of other researcher’s work however I’ve never had any biological research of my own to focus on.  In 2015 I was charged with helping the groups postdoc, Khadar Dudekula, with her proteomics profiling of eye tissue samples from the VISICORT project.  This area of research piqued my interest and from becoming more involved in the sample analysis and also attending the plenary meetings it became apparent that there was massive scope to carry this research forward in any number of directions.  Within my facility, I have a number of high-end mass spectrometers that can carry out various “omics” analyses so this PhD project seemed like a golden opportunity to utilise them to analyse the large number of samples available to me within Biostor Ireland.  There are thousands of samples within this biobank so it was sensible to narrow down my thesis question and focus on looking at a couple of conditions to start with (keratoconus and FECD).

“It is really gratifying to see how the VISICORT project has led to the development of a new and exciting approach for analysing the invaluable collection of our biological samples. We can look forward to being able to identify important new and medically important Biomarkers from Lisa’s VISICORT-inspired PhD.”

Professor Malcolm Walkinshaw, University of Edinburgh

What big questions do you want to answer?

I want to characterise keratoconus and FECD using a multi-omic approach combining proteomic, metabolomic and lipidomic analyses.  This will include developing a method for the efficient extraction of lipids, metabolites and proteins from a single sample, enabling the targeted and untargeted analyses of each eye tissue.  Extracting multiple “omes” in one step will ensure like for like comparisons and give a genuine snapshot of the biological status of the system. This will result in much better correlations between differences in metabolites/proteins and we can obtain greater insights into the metabolic pathways comparing healthy and disease states through interrogation and integration of the different omics datasets.  This method will be unique in eye tissue omics studies to date.

What are the biggest obstacles to answering these questions?

My biggest challenges in this project will be all the sample prep method development.  I’ve seen a similar one-step extraction method used before on plant material but never on the eye tissues that I’ll be working with.  All the different tissues, e.g. tears, aqueous humor, cornea, all have very different compositions so it’ll be interesting to see if the one method works with all sample types. 

Another challenge I’ll face is the data integration and interpretation.  To date, I have only ever run single omics experiments which require just one software analysis approach.  I’ll now have to find a way to integrate all the data generated from the proteomics, metabolomics and lipidomics analyses.  Fortunately, there’s a symposium towards the end of the year which deals with Multiomics data integration that I’ll be attending so hopefully this will give me some idea of the best way to deal with these large datasets.

How has VISICORT contributed to your project concept and research?

VISICORT Foundation Biobank brochure

Without VISICORT it may never have occurred to me to embark on my own PhD project.  Because the subject matter interested me so much and due to the large number of samples available in the Biostór it was an easy jump to design a project to expand on the profiling data already generated by mass spectrometry.  The challenge was distilling it down to look at a couple of biological questions as there were a large number of avenues we could have pursued.  The two plenary meetings I have presented at, the first in Berlin to pitch the idea of the PhD project and the second in Galway to present a more definite structure, have been invaluable to me.  Getting advice and suggestions from experts in the field has definitely shaped my work going forward.

New VISICORT publication from NUI Galway team

“TNF-α/IL-1β-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung” was published online in the FASEB Journal on May 20, 2019. The authors of the study from NUI Galway are Nick Murphy, Oliver Treacy, Kevin Lynch, Maurice Morcos, Paul Lohan, Linda Howard, Gerry Fahy, Matthew D. Griffin, Aideen E. Ryan, and Thomas Ritter.

Congratulations to the team!

FASEB J. 2019 May 20:fj201900047R. DOI: 10.1096/fj.201900047R. [Epub ahead of print]

Prof Ritter presents at ARVO 2019, Canada

VISICORT PI Prof Thomas Ritter of the NUI Galway presented at the recent Association for Research in Vision and Ophthalmology (ARVO) meeting in Vancouver, British Colombia, Canada. Thomas’ abstract, “Subconjunctival injection of low-dose mesenchymal stem cells promotes corneal allograft survival in a mouse cornea transplantation model” was presented Wednesday, May 1st during the “Corneal Neuropathy and Neovascularisation” session of the 2019 ARVO Annual Meeting which took place from April 28 – May 2, 2019.

The theme for the 2019 AVRO meeting was “From bench to bedside and back”.

PI Conor Murphy presents VISICORT at Royal Victoria Eye and Ear Hospital

VISICORT PI Prof and Consultant Ophthalmologist Conor C. Murphy of the RCSI (Royal College of Surgeons in Ireland) presented “What’s new (and old) in corneal transplantation” on the 5th of April 2019. The audience included a group of 40 surgical theatre nurses at the Royal Victoria Eye and Ear Hospital in Dublin. The VISICORT project concept and clinical trial were presented in slides 45-49.

Conor’s presentation can be viewed here.

VISICORT presentation in Berlin aims to recruit potential patients to the clinical trial

VISICORT PI Uwe Pleyer at Charité Universitätsmedizin Berlin organized a seminar entitled “Autologe Stammzelltherapie zur Prophylaxe der Immunreaktion bei Risikokeratoplastik”. The Anterior Segment Symposium on April 27th, 2019 in Berlin included a presentation on the VISICORT project with the aim to recruit potential patients for the Phase 1 trial.


Pictured above Prof. Dr Rieck and Prof. Dr Uwe Pleyer

VISICORT PI Nico Degauque, INSERM presents at Swedish Registry for Corneal Transplant

VISICORT PI Nicolas Degauque from INSERM in Nantes was an invited speaker at the annual meeting for participants in the Swedish Registry for Corneal Transplant which for many years have served as the registry for all Swedish and Danish patients undergoing corneal transplantation. The meeting took place at Riksgränsen at the very north of Sweden on April 11, 2019. Through Nico’s talk entitled “Innate-like functions of human TEMRA CD8 and their involvement in kidney allograft outcome”, he presented the recent advances in identifying biomarkers for transplant survival learned from kidney transplantations. It is the hope that the extension of these studies can provide biomarkers for corneal transplant survival.

The meeting was attended by VISICORT partners John Armitage from the University of Bristol and Jesper Hjortdal, Aarhus University Hospital.


VISICORT trial news announced in ARM March newsletter

The Alliance for Regenerative Medicine’s March 14, 2019 newsletter included a recent update on the VISICORT clinical trial regulatory approval. You can read the piece in the newsletter’s Clinical Updates section.

VISICORT at Biobanking Summit 2019

Managing Director of Biostór Ireland Peadar MacGabhann will present “Establishment Of The VISICORT Foundation Biobank For Eye Disease” at the Biobanking Summit 2019 which will be held in Porto, Portugal on February 14th and 15th. Here, VISICORT Biobank brochures will be on hand for education and information, and to promote the use of it by researchers.

The Biobanking 2019 conference will bring together the world’s leading experts in biorepositories, policy makers, and scientific actors to strengthen knowledge in biobanking as well as explore future advances in the field of biosampling for precision medicine, drug development and health research.

Read the entire meeting agenda here.